GlaxoSmithKline plans to increase its share in Indian subsidiary GSK Pharmaceuticals to 75 percent
London-listed GlaxoSmithKline (GSK) plans to spend a potential Rs 6,400 crore ($1.03 billion) to increase its share in Indian subsidiary GSK Pharmaceuticals to 75 percent from the current 50.7 percent, through a voluntary open offer.
(This story appears in the 07 March, 2014 issue of Forbes India. To visit our Archives, click here.)